《新股消息》智欣集團(02187.HK)公開發售超購24倍 一手中籤率10%
內地混凝土建材製造商及供應商智欣集團(02187.HK)公布招股結果,發售價定於1.5元,公開發售錄超購24.24倍,經重新分配後,公開發售股數增至20%。每手8,000股,中籤率為10%。該股將於明日(3月26日)上市,新華匯富為獨家保薦人。
公司預計,發售所得款項淨額約2.41億元,當中82.7%將用於擴大預製混凝土構件廠房的預製混凝土構件產能;3.6%用於引入企業資源規劃系統以提升資訊科技系統;3.2%用於改善環境保護系統。另外,部分款項用於購置攪拌車和混凝土泵車、以及用作一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.